<![CDATA[Preclinical data show potential of CD46-targeted combination therapy in prostate cancer]]>
Flavell and Bidkar explained that the study was built around CD46, a cell-surface antigen broadly overexpressed in multiple malignancies, including prostate cancer. Their team has been developing 2 distinct CD46-directed therapeutic platforms: the ADC YS5- …